Psychiatry

In the complete response letter, the FDA classified deficiencies in the Abbreviated New Drug Application for ketamine as MINOR.

A study found that adding depression to Life's Essential 8 provides minimal improvements in predicting cardiovascular and all-cause mortality risk.

A new meta-analysis found elevated triglyceride levels in patients with major depressive disorder, potentially explaining the link between depression and cardiovascular risks.

A new study identifies antipsychotics to avoid for patients with schizophrenia who have cognitive deficits, including haloperidol, fluphenazine, and clozapine.

Research from Spain suggests long-term opioid use to treat fibromyalgia pain significantly raises the risk of depression, anxiety and sleep disorders in patients.

Factors, including older age at onset and longer length of stay, may predict longevity for schizophrenia in psychiatric long-term care settings.

Second-generation long-acting injectables were particularly underutilized, and especially among older patients.

A short-term rise in air pollution levels between neighboring days was significantly linked to an increased risk of schizophrenia hospitalizations in China.

Findings suggest obstetric complications are associated with more severe psychopathological phenotypes in schizophrenia and related disorders.

A study of more than 130k with schizophrenia revealed significant variability in relapse and treatment failure rates across different antipsychotics.

Being female and having bipolar II disorder were independent risk factors for serious AEs in a new study.

Findings highlight high healthcare resource utilization and costs but low psychotherapy utilization, frequent relapse, and pharmacologic therapy discontinuation.

A recent study shows the FDA's black-box warnings on antidepressants have led to decreased usage among youth, with an increase in suicide attempts and deaths observed.

A study reveals that individuals with schizophrenia spectrum disorders experience high rates of comorbid mental health conditions and receive minimally adequate treatment.

A study links conversion therapy with worse mental health, such as PTSD and depression, showing a need for legislative action and support for LGBTQ+ individuals.

This Month in Review features the approval of trospium chloride capsules (Cobenfy) as well as other clinical trials in the psychiatry field.

The FDA approves Cobenfy, the first pharmacological approach to treating schizophrenia since the 1970s.

A new study finds causal links between schizophrenia and MDD on IBS, highlighting the need for integrated care addressing both psychiatric and gastrointestinal symptoms.

Inpatients receiving brief cognitive behavioral therapy had a 60% reduced likelihood of suicide attempts and a 71% reduced rate of psychiatric readmissions post-discharge.

A report shows only 24%, 56%, and 62% of patients meet the criteria PSIL-AT for depression according to low-bound, mid-range, and upper-bound estimates, respectively.

A new study suggests lower cognitive functioning may be a risk factor for natural cause mortality in people with schizophrenia.

A recent study saw prescription fills for stimulants, and antidepressants increased from 2019 to 2022 but decreased for opioids.

In an interview, lead investigator Lauren Moran, MD, shared how the results inform clinical practice on safe amphetamine dosing.

A new study highlights the need for caution when prescribing high-dose amphetamines (≥ 30 mg) due to their psychosis and mania risk.

A phase 3 trial found mirtazapine ineffective in reducing breathlessness in respiratory disease patients, urging caution with off-label antidepressant use.

A post-hoc analysis of the STEP trials found semaglutide for weight management doesn’t increase depression or suicidal thoughts in individuals without major mental disorders.

This month in review highlights MDMA-assisted therapy coverage, experiences with zuranolone a year after its approval, and early positive data on potential treatments.

A phase 2 trial met its primary endpoint, showing NBI-1117568, the first M4 selective agonist, is effective and safe at treating adult schizophrenia.

Michigan Medicine and U-M research finds a bidirectional link between mental health disorders and chronic diabetes complications, urging comprehensive screenings.

A new study significantly demonstrated semaglutide, but not liraglutide, is associated with suicidal ideation.